pharmaphorum

SEPTEMBER 8, 2023

Lift for Roche as Alnylam drug lowers blood pressure Phil.Taylor Fri, 08/09/2023 - 07:31 Bookmark this

104

104

pharmaphorum

JULY 17, 2023

Alnylam showcases long-acting amyloid drug at AAIC Phil.Taylor Mon, 17/07/2023 - 08:47 Bookmark this

98

98

STAT

FEBRUARY 23, 2024

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

106

106

Fierce Pharma

SEPTEMBER 13, 2023

After Alnylam faced FDA doubts about its bid to expand RNA-silencing drug Onpattro into a rare heart disease called transthyretin amyloidosis cardiomyopathy (ATTR-CM), the company has picked up key | An FDA advisory committed voted in favor of Alnylam's bid to expand its RNA-silencing drug Onpattro into the rare heart disease called ATTR-CM.

FDA 84

FDA 84

STAT

JULY 24, 2023

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease. If things go well, Roche could pay Alnylam up to $2.8

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

STAT

JULY 24, 2023

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease. If things go well, Roche could pay Alnylam up to $2.8

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceutical Companies 97

Fierce Pharma

MAY 30, 2023

Alnylam sticks with aggressive litigation strategy against Pfizer and Moderna, filing yet another patent lawsuit zbecker Tue, 05/30/2023 - 10:24

111

111

Fierce Pharma

SEPTEMBER 11, 2023

Ahead of an important advisory committee meeting, the FDA has raised serious questions about Alnylam’s bid to expand Onpattro into a much larger group of patients with transthyretin amyloidosis (AT | The FDA has raised questions about Alnylam's Onpattro as the company seeks to expand the drug into a much larger group of patients with transthyretin (..)

FDA 103

FDA 103

Fierce Pharma

OCTOBER 2, 2023

With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam esagonowsky Mon, 10/02/2023 - 13:15

FDA 91

FDA 91

Fierce Pharma

MAY 16, 2023

Moderna hits back at Alnylam's 'baseless' patent infringement claims zbecker Tue, 05/16/2023 - 15:59

89

89

STAT

AUGUST 3, 2023

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

FDA 91

FDA 91

Fierce Pharma

FEBRUARY 21, 2023

Chasing Pfizer, Alnylam to face FDA Adcomm for Onpattro’s rare heart disease bid aliu Tue, 02/21/2023 - 09:53

FDA 90

FDA 90

Pharmaceutical Technology

JULY 24, 2023

Roche has announced a collaboration with Alnylam for the development and marketing of zilebesiran to treat hypertension.

52

52

PharmaVoice

OCTOBER 12, 2023

Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.

52

52

Fierce Pharma

JANUARY 19, 2023

Alnylam, PTC Therapeutics rare disease drugs win backing from England's NICE zbecker Thu, 01/19/2023 - 11:53

79

79

STAT

SEPTEMBER 8, 2022

Detailed data from a successful heart disease study show a therapy developed by Alnylam Pharmaceuticals performed significantly better than placebo, but the magnitude of its benefit will stir debate among cardiologists and investors on what could be a blockbuster medicine.

Hospitals 94

Hospitals 94

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemdisiran is under clinical development by Alnylam Pharmaceuticals and currently in Phase III for Myasthenia Gravis.

40

40

pharmaphorum

JUNE 14, 2022

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler, more patient-friendly dosing regimen. Amvuttra – which is Alnylam’s fourth approved product – has been tipped to become a $1.8

FDA 52

FDA 52

STAT

FEBRUARY 16, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at pharma’s struggle to make inroads in D.C., the curious story of the latest FDA drug approval, and a twist on the year’s biggest biotech event.

FDA 82

FDA 82

pharmaphorum

OCTOBER 21, 2021

UK cost-effectiveness watchdog NICE is set to recommend NHS use of Alnylam’s gene-silencing therapy Givlaari in England and Wales for the rare disease acute hepatic porphyria (AHP), after its advisors issued a positive verdict on the drug. ” The post Alnylam gets NICE backing for porphyria therapy Givlaari appeared first on.

Documentation 98

Documentation Compounding Hospitals 98

pharmaphorum

JULY 25, 2023

Roche buys into Alnylam's twice-yearly blood pressure drug Phil.Taylor Tue, 25/07/2023 - 08:09 Bookmark this

52

52

Fierce Pharma

APRIL 19, 2023

Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up aliu Wed, 04/19/2023 - 14:39

76

76

pharmaphorum

MARCH 17, 2022

Alnylam claims it is owed a slice of the massive revenues booked by Pfizer and Moderna for their mRNA-based COVID-19 vaccines, because they are both infringing patents its holds on a delivery technology. The post Alnylam sues Pfizer, Moderna over COVID-19 vaccines appeared first on.

Vaccines 52

Vaccines Immunization 52

pharmaphorum

OCTOBER 12, 2021

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track their symptoms. The post Alnylam launches digital tool for AATR amyloidosis patients appeared first on.

Labelling 52

Labelling 52

Pharmaceutical Technology

AUGUST 11, 2022

Alnylam Pharmaceuticals and collaborators have identified rare mutations in the INHBE gene that is expressed in the liver, related to a lower waist-to-hip ratio for body mass index (BMI), which is often used as an indicator of abdominal fat and is correlated with the risk of type 2 diabetes (T2D) and coronary heart disease.

52

52

pharmaphorum

AUGUST 27, 2020

Alnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing and how it could offer a route to target the current coronavirus pandemic. The post Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast appeared first on.

52

52

STAT

OCTOBER 18, 2023

During a nearly two-decade stint as Alnylam’s founding CEO, John Maraganore took a promising but unproven approach for treating genetic disease and built a new class of medicines and what is now a nearly $21 billion company. His next goal? Helping the next generation of budding biotech entrepreneurs.

131

131

PharmaShots

MAY 22, 2023

results with no new safety concerns Ref: Businesswire | Image: Alnylam Related News:- Alnylam Expands its Collaboration with Medison Pharma to Commercialize RNAi Therapies PharmaShots! who received PBO in the DB period which then appeared to slow or stabilize after initiating patisiran in the OLE period.

40

40

STAT

SEPTEMBER 14, 2023

What does Covid-19 have in store for the winter? When are good data not good enough? And how many would-be Wegovys are there? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.

FDA 133

FDA 133

STAT

OCTOBER 9, 2023

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

FDA 129

FDA 129

pharmaphorum

DECEMBER 22, 2023

AstraZeneca and Ionis get first approval for ATTR polyneuropathy drug Wainua (eplontersen), a rival to drugs from Alnylam and Pfizer

FDA 101

FDA 101

STAT

SEPTEMBER 13, 2023

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

FDA 131

FDA 131

Pharma Times

OCTOBER 7, 2021

Leading RNA intereference (RNAi) therapeutics company, Alnylam, has been welcomed as the latest partner in the Medicines Manufacturing Innovation Centre, to transform the manufacturing process of oligonucleotide therapies.

35

35

PharmaVoice

OCTOBER 2, 2023

The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer.

FDA 98

FDA 98

STAT

FEBRUARY 22, 2024

First, former Alnylam Pharmaceuticals CEO John Maraganore and STAT’s Matthew Herper join us to discuss the legacy of AbbVie chief executive Richard Gonzalez, who announced his retirement this week. Did Humira break the system? And can you CRISPR a fetus?

109

109

STAT

APRIL 7, 2024

ATLANTA — New trial results show that a drug candidate from Alnylam Pharmaceuticals can lead to long-lasting blood pressure reduction when taken with certain commonly used pills, but some doctors are questioning how much the drug would actually be used in clinical practice.

117

117

Fierce Pharma

OCTOBER 9, 2023

Despite an endorsement from an advisory committee, the FDA has come to a different conclusion on the benefit-risk profile for Alnylam’s Onpattro in the rare heart disease transthyretin amyloidosis | Despite an endorsement from an advisory committee, the FDA has come to a different conclusion on the benefit-risk profile for Alnylam’s Onpattro in the (..)

FDA 83

FDA 83